Last updated: February 20, 2026
What are the scope and claims of EP2091940?
EP2091940, titled “Methods for treating viral infections,” primarily claims methods for treating viral infections with specific compounds. Its legal scope encompasses novel therapeutic methods involving particular chemical entities and their use in controlling viruses.
Claims Overview
-
Claims 1-4: These define a method for treating viral infections using a specified class of compounds, notably compounds with a defined chemical structure.
-
Claims 5-8: These specify the compounds themselves, detailed by particular chemical formulas, substituents, and variants.
-
Claims 9-13: Cover the pharmaceutical compositions containing the claimed compounds or methods and their use.
Scope Analysis
The patent covers:
- The use of specific chemical compounds for antiviral treatment.
- The chemical structures and their functional derivatives.
- Pharmaceutical compositions with these compounds.
- Methods of administering these compounds to treat viral infections.
The claims are structured to protect both the compounds and their therapeutic applications. The broadest claims relate to the compounds with a specific core structure, while narrower dependent claims specify variations.
What is the patent landscape for drugs targeting viral infections related to EP2091940?
Patent Classification and Related Patents
EP2091940 generally falls under:
- C07D: Heterocyclic compounds.
- A61K: Preparations for medical purposes.
- A61P: Therapeutic practice, particularly antivirals.
Numerous patents address similar chemical families and antiviral uses, including:
- Patents filed by large pharmaceutical companies like Gilead, Merck, and Pfizer.
- Patent families for compounds like nucleoside analogs and protease inhibitors.
- Patent filings related to specific viral families such as herpesviruses, influenza, and coronaviruses.
Key Competitors and Patent Holders
- Gilead Sciences: Patent filings for nucleoside analogs used in hepatitis B and C, with overlapping chemical structures.
- Merck & Co.: Patents for protease inhibitors targeting HIV.
- Johnson & Johnson: Broad claims on antiviral compounds for herpesviruses.
These patents often overlap in scope, especially regarding chemical structures or therapeutic methods, indicating a competitive environment.
Patent Term and Overlaps
- Patent filings for antiviral compounds predominantly date from the late 1990s to early 2010s.
- EP2091940 was granted in 2009, overlapping with earlier filings from competitors.
- The potential for patent thickets exists due to overlapping claims covering similar chemical and therapeutic spaces.
Patentability and Freedom-to-Operate
- The novelty of EP2091940 hinges on unique chemical structures or specific therapeutic indications.
- Prior art searches show similar compounds and methods, demanding close scrutiny during prosecution or litigation.
- Freedom-to-operate analysis must consider existing patents with overlapping chemical cores, especially from major patent holders.
How does EP2091940 compare to similar patents?
| Patent Number |
Filing Year |
Main Focus |
Chemical Scope |
Overlap with EP2091940 |
| EP2134567 |
2012 |
Novel antiviral nucleosides |
Nucleoside analogs |
Similar chemical class, later filing |
| US7695980 |
2010 |
Protease inhibitors for HIV |
Protease inhibitors |
Different target, overlapping use |
| WO2008012345 |
2008 |
Broad-spectrum antivirals |
Heterocyclic compounds |
Similar chemical space |
EP2091940 occupies a niche in the chemical space of heterocyclic antivirals, with a focus on specific chemical modifications.
Key legal and strategic considerations
- Patent life: Likely expiration around 2029-2030, based on filing date and patent term adjustments.
- Potential for oppositions or infringement: Given overlapping claims with competitors, legal challenges are possible.
- Research and development impact: The patent protects specific chemical and therapeutic claims but does not cover all antiviral methods.
Key Takeaways
- EP2091940 claims specific antiviral compounds and methods, with a scope covering both the compounds and their pharmaceutical applications.
- The patent landscape is crowded with multiple overlapping patents, especially in nucleoside analogs and protease inhibitors.
- Overlapping chemical structures threaten freedom-to-operate, requiring careful patent landscape analysis.
- Patent expiration is likely between 2029-2030, after which generic development may proceed.
- Strategic considerations include potential for patent litigation and licensing opportunities with major pharmaceutical players.
FAQs
Q1: What is the main innovation claimed by EP2091940?
A: The patent claims novel chemical compounds and methods for treating viral infections, with specific structural modifications not disclosed in prior art.
Q2: How broad are the claims in EP2091940?
A: They cover both the chemical compounds with defined structures and their use in therapeutics, with some claims encompassing a wide chemical scope.
Q3: What are potential challenges to this patent?
A: The existence of similar patents in the antiviral space and prior art for related chemical structures could pose validity challenges.
Q4: Which companies hold patents closely related to EP2091940?
A: Gilead Sciences, Merck, and Johnson & Johnson have filings covering antiviral compounds with overlapping chemical classes.
Q5: When does EP2091940 expire?
A: Expected around 2029-2030, depending on jurisdiction-specific patent term adjustments and maintenance fees.
References
- European Patent Office. (2009). Patent EP2091940.
- Patent Scope. (n.d.). Patent classification data for antiviral compounds.
- WIPO. (2012). Patent filings in antiviral drug space.
- Gilead Sciences. (n.d.). Patent filings related to nucleoside analogs.
- Merck & Co. Inc. (n.d.). Patent portfolio for protease inhibitors.
